Triparna Sen
 | This article, Triparna Sen, has recently been created via the Articles for creation process. Please check to see if the reviewer has accidentally left this template after accepting the draft and take appropriate action as necessary.
Reviewer tools: Inform author |
| This article, Triparna Sen, has recently been created via the Articles for creation process. Please check to see if the reviewer has accidentally left this template after accepting the draft and take appropriate action as necessary.
Reviewer tools: Inform author |
Triparna Sen | |
|---|---|
| Born | 1983 Kolkata, India |
| Alma mater | University of Calcutta (BSc) (MSc) Jadavpur University (PhD) |
| Known for | Understanding the biology and identifying therapeutic targets in small cell lung cancer. |
| Awards | AAAS Martin and Rose Wachtel Cancer Research Award (2021) |
Triparna Sen (born 1983) is an American-Indian cancer researcher and biologist. Her research is based on translational oncology, DNA damage response, cancer immunotherapy, drug development, and small-cell lung cancer.[1][2]
Career
Sen received her bachelor’s degree in physiology followed by a master’s degree in genetics from University of Calcutta. Later, she completed her doctorate in science from the Jadavpur University, Kolkata, India.[1]
Sen has worked at Memorial Sloan Kettering Cancer Center in New York and MD Anderson Cancer Center in Texas and identified that DNA damage response (DDR) proteins are effective therapeutic targets for small-cell lung cancer treatment and that targeting DDR promotes antitumor immunity through the activation of innate immune signaling.[1][2]In addition, she is a researcher and associate professor in the Department of Oncological Sciences, and the Director of the Lung Cancer PDX Platform at the Icahn School of Medicine at Mount Sinai, New York, USA.[3]
Throughout her career Sen has received several awards and recognitions for her scientific contributions and research including AAAS Martin and Rose Wachtel Cancer Research Award in 2021.[2] Her research papers are published in journals, including Cancer Discovery, Clinical Cancer Research, and Cancer Research.[4]
Selected publications
- Triparna Sen, Elisa de Stanchina, Charles M. Rudin, Dan Hasson; et.al. De Novo and Histologically Transformed Small-Cell Lung Cancer Is Sensitive to Lurbinectedin Treatment Through the Modulation of EMT and NOTCH Signaling Pathways. Clin Cancer Res 1 September 2023; 29 (17): 3526–3540. https://doi.org/10.1158/1078-0432.CCR-23-0471
- Sen T, Della Corte CM, Milutinovic S; et.al. Combination Treatment of the Oral CHK1 Inhibitor, SRA737, and Low-Dose Gemcitabine Enhances the Effect of Programmed Death Ligand 1 Blockade by Modulating the Immune Microenvironment in SCLC. J Thorac Oncol. 2019 Dec;14(12):2152-2163. doi: 10.1016/j.jtho.2019.08.009.
- Sen T, Quintanal-Villalonga A, Taniguchi H, Zhan YA, Hasan MM, Chavan SS; et.al. Multiomic Analysis of Lung Tumors Defines Pathways Activated in Neuroendocrine Transformation. Cancer Discov. 2021 Dec 1;11(12):3028-3047. doi: 10.1158/2159-8290.CD-20-1863.
- Triparna Sen, Pan Tong, Lixia Diao, Lerong Li, Youhong Fan; et.al. Targeting AXL and mTOR Pathway Overcomes Primary and Acquired Resistance to WEE1 Inhibition in Small-Cell Lung Cancer. Clin Cancer Res 15 October 2017; 23 (20): 6239–6253. https://doi.org/10.1158/1078-0432.CCR-17-1284
References
- ^ a b c "ফুসফুস ক্যানসারের চিকিৎসায় নয়া দিশা, আশার আলো দেখালেন বঙ্গতনয়া". sangbadpratidin. Retrieved 2024-05-21.
- ^ a b c Cariz, Joseph (2021-08-11). "Scientist Honored for Discovering a Weakness in Aggressive Lung Cancer". American Association for the Advancement of Science. Retrieved 2024-05-21.
- ^ "Triparna Sen | Mount Sinai - New York". Mount Sinai Health System. Retrieved 2024-05-22.
- ^ "New targets for lung cancer treatment". Drug Discovery News. Retrieved 2024-05-22.
Sources
 | This article about a biologist is a stub. You can help Wikipedia by expanding it. |
  | This article about a biologist from the United States is a stub. You can help Wikipedia by expanding it. |